Mycobacteria: treatment approaches and mechanisms of resistance.

Published

Journal Article (Review)

First-line drugs for tuberculosis treatment include isoniazid, rifampin, ethambutol, streptomycin, and pyrazinamide. Molecular mechanisms for resistance to each of these drugs have been elucidated. In every case, resistance is conferred by mutations in existing genes, not by the acquisition of new genetic material. Drug resistance is a major problem worldwide, but the rates vary widely among countries and within countries. Acquired resistance in previously-treated patients is much more common than primary resistance in patients with no previous treatment. High rates of acquired resistance have been reported from referral centers in Saudi Arabia and Lebanon. Successful TB treatment requires prolonged therapy with at least two active drugs. Directly-observed therapy (DOT) improves success rates and reduces the risk of acquired resistance. TB due to susceptible strains can be cured in over 95% of cases.

Full Text

Duke Authors

Cited Authors

  • Frothingham, R

Published Date

  • July 2000

Published In

Volume / Issue

  • 48 / 4

Start / End Page

  • 248 - 254

PubMed ID

  • 11214197

Pubmed Central ID

  • 11214197

International Standard Serial Number (ISSN)

  • 0023-9852

Language

  • eng

Conference Location

  • Lebanon